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Abstract: Adult or somatic stem cells hold great promise for tissue regeneration. Currently, one major sci-
entific interest is focused on the basic biology and clinical application of mesenchymal stem cells. Adipose
tissue-derived stem cells share similar characteristics with bone marrow mesenchymal stem cells, but have
some advantages including harvesting through a less invasive surgical procedure. Moreover, adipose tis-
sue-derived stem cells have the potential to differentiate into cells of mesodermal origin, such as
adipocytes, cartilage, bone, and skeletal muscle, as well as cells of non-mesodermal lineage, such as hepa-
tocytes, pancreatic endocrine cells, neurons, cardiomyocytes, and vascular endothelial cells. There are,
however, inconsistencies in the scientific literature regarding methods for harvesting adipose tissue and
for isolating, characterizing and handling adipose tissue-derived stem cells. Future clinical applications of
adipose tissue-derived stem cells rely on more defined and widespread methods for obtaining cells of cli-
nical grade quality. In this review, current methods in adipose tissue-derived stem cell research are dis-
cussed with emphasis on strategies designed for future applications in regenerative medicine and possi-
ble challenges along the way.
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Resumo: As células-tronco adultas ou somáticas detêm grande promessa para a reparação e regeneração
de tecidos. Atualmente, o interesse dos cientistas é contínuo na investigação da biologia de células-tronco
mesenquimais, tanto em aspectos básicos, quanto no potencial de aplicações terapêuticas. As células-tron-
co adultas derivadas do estroma do tecido adiposo, em comparação com as células-tronco derivadas do
estroma da medula óssea, apresentam como vantagem o método fácil de obtenção da fonte tecidual. As
células-tronco adultas derivadas do estroma do tecido adiposo apresentam potencial para se diferenciarem
em células de tecidos mesodérmicos, como os adipócitos, as cartilagens, os ossos e o músculo esquelético
e não mesodérmicos, como os hepatócitos, as células pancreáticas endócrinas, os neurônios, os hepatóci-
tos e as células endoteliais vasculares. Entretanto, os dados disponíveis na literatura científica sobre as ca-
racterísticas das células-tronco adultas derivadas do estroma do tecido adiposo e os procedimentos para sua
obtenção e manipulação no laboratório são inconsistentes. É necessário o desenvolvimento de metodolo-
gias e procedimentos eficazes de isolamento dessas células para obtenção de células em quantidade e qua-
lidade suficientes para aplicação terapêutica. Nesta revisão, são discutidos os métodos correntes de coleta
de tecido adiposo, isolamento e caracterização de células-tronco adultas derivadas do estroma do tecido
adiposo, com ênfase na futura aplicação em medicina regenerativa e nos possíveis desafios nesse recente
campo da ciência. 
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INTRODUCTION
By definition, stem cells are characterized by
being primitive (undifferentiated or non-specialized)
and by having the ability to generate not only new
stem cells, but also a diverse range of specialized cell
types under certain physiological and experimental
conditions. 1-2 In this process of self-renewal and dif-
ferentiation, the stem cell can go through two basic
division processes: a) the deterministic model, which
corresponds to the division of a stem cell that gener-
ates a new stem cell and a cell that will differentiate
(progenitor cell) and b) the random or stochastic
model, in which some stem cells generate only new
stem cells while others generate differentiated cells. 
Regarding their differentiation potential, stem
cells are classified into four basic categories: a) totipo-
tent, capable of differentiating into all the tissues that
form the human body, including the placenta and
embryonic membranes (zygote-derived cells); b)
pluripotent, present in the inner cell mass of a blasto-
cyst and capable of differentiating into any of the
three germ layers (ectoderm, mesoderm, and endo-
derm); c) multipotent, which differentiate into vari-
ous cell types of a single germ layer; d) oligopotent,
which differentiate into few cells of a single germ
layer, and e) unipotent, which differentiate into only
one type of cell of a single germ layer. 2-3
The basic difference about the nature of stem
cells lies in the existence of embryonic stem cells
(totipotent or pluripotent) 1 and adult or somatic
stem cells, precursor cells of the already developed
organism. 1-3 Recently, to improve the plasticity [I] 4 of
adult stem cells, researchers were able to increase the
differentiation potential of these cells, by a) somatic
cell nuclear transfer 5 and b) genetic reprogramming
of somatic stem cells to the embryonic state, by the
introduction of pluripotency-determining genes
(OCT-4, SOX-2, KLF-4, cMYC). These cells are called
induced pluripotent stem cells or IPs cells. 6
Pluripotent stem cells are the only ones capable
of differentiating in vitro, inherently and sponta-
neously, into cells of the three germ lineages.
Pluripotent stem cells are characterized by a high pro-
liferation capacity, typical morphology and expression
of specific markers (e.g. SSEA-3, SSEA-4, OCT-4, SOX-
2, NANOG, KLF4), and the ability to form teratomas. 2,3,7,8
Adult stem cells (ASC) have been isolated and
characterized in various body tissues, such as bone
marrow, umbilical cord, encephalon, epithelium,
dental pulp and, more recently, adipose tissue.
However, ASC have a limited capacity of
differentiating into the various tissues of the human
body. 9 Some scientists call them post-natal cells
because they are found in the umbilical cord and
other tissues of newborn babies. ASC are responsible
for maintaining tissue homeostasis by renewing cells
lost due to maturation, aging or damage. 9 For this
reason, they hold great promise for tissue
regeneration and repair.   
A type of ASC that has been receiving more
attention in preclinical and clinical studies about cell
therapy is the mesenchymal stem cell [II] (MSC),
which can be isolated from many biological sources,
such as the umbilical cord, bone marrow, adipose
tissue and fetal liver. 9,10 According to the scientific
literature, 9-11 MSC are considered great candidates for
cellular therapy due to the following criteria: a) they
are easily harvested; b) they can be harvested from the
patient himself; c) possibility of harvesting an
adequate number of cells for transplantation, due to
the high cellular proliferation in vitro, d) multipotent
capacity of cell differentiation, e) easy laboratory
handling, f) they have little immunogenicity, and g)
they have the ability to integrate into the host tissue
and interact with the surrounding tissue. However,
the critical issue about these criteria is that scientists
still ignore all the factors involved in cell
differentiation and self-renewal (controlled by specific
genes) and the chronic in vivo effects of MSC
infusion. But the capacity that MSCs have to
differentiate into mesodermal tissue, 10,11 such as
musculoskeletal, bony, cartilaginous, and adipose
tissue, strengthens their potential of use in
regenerative medicine. 
Circumjacent factors (internal and external fac-
tors) are extremely important for their maintenance,
that is, their self-renewal and differentiation. This
complex and dynamic microenvironment, which
sends and receives signals via cellular and non-cellu-
lar mediators, is called niche. 12 Scientists still ignore
the mechanisms that establish niches.
Another factor that limits the use of ASC is the
low amount of telomerase, because telomeres are
shortened in these cells; this limits their cell prolifer-
ation capacity. 7 Scientists have recently suggested age
as a limiting factor for the use of ASC due to the accu-
mulation of intrinsic events, such as DNA mutations,
as well as extrinsic factors (niche alterations). It is
thought that with aging the mechanisms responsible
for the suppression of cancer development, such as
senescence or apoptosis, may induce the decline of
[I] Plasticity: recently-discovered capacity of stem cells to expand their potential beyond tissues from which they are derived
[II] MSC: Mesenchymal or stromal stem cells
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the replicating function of stem cells. 13
The stromal vascular fraction (SVF) of adipose
tissue has been the focus of recent research on adi-
pose-derived stem cells – ADSC. 9,11,14,15 Some studies
indicate that this tissue compartment is a rich source
of pluripotent cells 14-16, although some scientists ques-
tion the pluripotentiality of ADSC. 17 ADSC, however,
share characteristics of ASC and their application in
pharmacological and clinical studies, particularly in
the search for treatment of degenerative diseases, has
been considered. 14,16
The adipose tissue is highly complex and is
constituted by mature adipocytes, preadipocytes,
fibroblasts, vascular smooth muscle cells, endothelial
cells, monocytes, and macrophages, 18 and lympho-
cytes. 19 There is confusion in the scientific literature
about the terms used to describe multipotent stem
cells of adipose tissue, such as ADSC, human
processed lipoaspirate (PLA) cells, preadipocytes or
SVF. The acronym SVF corresponds to ADSC and
describes the cells obtained immediately after the
digestion of collagenase. 20,21 In this review, we will
adopt the term ADSC for stem cells present in the adi-
pose tissue. 
Some scientists believe that the adipose tissue
is a promising source of ASC for therapeutic applica-
tions because it is available in large amounts (100 ml
up to 1 liter) through liposuction and with minimal
morbidity. 22,23 However, very few review studies in the
scientific literature explore the cellular and molecular
characterization of ADSC. 20,21 In tissue bioengineer-
ing, the use of ADSC has been considered in the treat-
ment of chronic degenerative diseases; for instance,
in X-linked muscular dystrophy in the mouse. 24 They
are also promising in reconstructive surgical treat-
ment, of traumatic or non-traumatic origin, as in
hereditary or acquired lipoatrophy. 25,26
The objective of this review is to gather informa-
tion from the scientific literature about tissue prepara-
tion for cellular and molecular characterization, the
capacity of differentiation of ADSC and their future
applicability in regenerative medicine, as well as the
possible challenges in this recent scientific field.
THE ADIPOSE TISSUE
In human adults, brown adipose tissue (BAT) is
practically absent. However, the localized deposit of
white adipose tissue (WAT) is present in various areas
of the organism, involving or infiltrating organs and
internal structures. 27,28 Anatomically, BAT is distrib-
uted in the organism as subcutaneous adipose tissue
(SAT) and visceral adipose tissue (VAT). In addition to
adipocytes, BAT contains a matrix of connective tissue
(collagenous and reticular fibers), nervous tissue,
stromal-vascular cells, lymphatic nodules, immune
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cells (leukocytes, macrophages), fibroblasts, and stem
cells. 27,28
Over the last few years, it has been observed
that the adipose tissue is not only an energy storer
and provider, but also a dynamic, hormone-producing
organ, which is involved in a variety of physiological
and physiopathological processes, because it is able to
secrete many proteins called adipokines (cytokines). 27
The protein structure and the physiological
function of the adipokines identified so far are highly
varied. Adipokines may be grouped based on their
main function: immunologic (e.g. adipsin), cardiovas-
cular, metabolic or endocrine (e.g. adiponectin). 18
1. Adipogenesis 
The analysis of adipogenesis (adipose tissue dif-
ferentiation process) aims at unfolding the molecular
and cellular basis of adipose tissue development. 27
The components involved in cell-cell interaction or in
the cellular matrix are important to the regulation of
the differentiation process of adipocytes. 27 Both hor-
monal and nutritional signs may affect this differenti-
ation in a positive and negative manner.  
The differentiation of the preadipocyte into
adipocyte is a highly controlled process.  Adipogenic
transcription factors, including the peroxisome prolif-
erator-activated receptor (PPAR) gamma and the sterol
regulatory element -binding protein (SREBP-1c), and
the CCAAT/enhancer binding protein - C/EBPs play a
key role in the complex transcriptional cascade that
occurs during adipogenesis. 28,29
The PPAR γ are responsible for the differentia-
tion of adipocytes and lipid storage. The PPAR γ are
the key regulators of adipocyte differentiation, stimu-
lating an increase in the expression of various genes.
The activation of these receptors leads to the reduc-
tion of adipokine secretion (tumor necrosis factor-
alpha and leptin) and to the increase of adiponectin. 28.29
The PPAR γ may be activated by synthetic com-
pounds denominated thiazolidinediones (TZD),
which are clinically used as antidiabetic agents. 28,29
The SREBP protein (orphan nuclear receptor)
is a transcription factor originally cloned from the adi-
pose tissue of a mouse. The SREBP transcription fac-
tor is important to lipid homeostasis because it
increases the expression of the gene responsible for
lipogenic enzymes; however, its adipogenic function
and the relation with PPAR Á remain unclear. 28,29
C/EBPs are members of the b-zip family (DNA
binding domain), which contains a leucine zipper-like
domain necessary for dimerization. The isoforms of
C/EBP (·, ‚ e ‰) are highly expressed in the
adipocytes and induced during adipogenesis. C/EBP·
is important in the differentiation of preadipocytes
into adipocytes and acts in the conversion of fibrob-
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lasts into adipocytes. C/EBP‚ also induces adipogene-
sis, probably by stimulating PPAR γ expression, whose
gene contains C/EBP sites in its promoter region. It
has been shown that PPAR γ is a potent stimulant of
the adipocyte cell differentiation cascade and acts syn-
ergically with C/EBP· to promote it or to induce the
differentiation of fibroblasts into adipocytes. 28,29 
VED STEM CELLS 
The adipose tissue is an abundant source of
cells for autologous transplants and is easily obtained
through liposuction, a cheaper and less invasive pro-
cedure than bone marrow puncture. Nonetheless,
there is still no consensus among researchers about
the nomenclature and plasticity of ADSC. 17,20,21
Comparative analysis of MSC, bone marrow
stromal cells (BMSC), ADSC, and umbilical cord stem
cells (UCSC) showed that ADSC are not different in
relation to morphology and immunologic phenotype
in comparison with BMSC and UCSC. 10,15. However,
the frequency of ADSC in the adipose tissue is higher
than that of BMSC [III] in the medullary stroma. 30-33
The cell proliferation rate of ADSC is higher than that
of BMSC. 31
Approximately 2 - 6 x108 cells in 300 mL of adi-
pose tissue can be obtained from lipoaspirate.
However, this number of ADSC may vary depending
on the method for harvesting stem cells. In fact, data
from the literature about the isolation of ADSC indi-
cate that according to the surgical procedure [IV] and
the laboratorial method employed, a different num-
ber of ADSC may be obtained from the same amount
of adipose tissue, 30-35 as well as ADSC with varied char-
acteristics and viability. 34 The viability of ADSC is,
however, apparently not altered after cryopreserva-
tion of the aspirated material. 35
Despite the existence of very few clinical stud-
ies, the number of ADSC appears to remain the same
in relation to the anatomical region. 32 Nonetheless,
the human adipose tissue shows metabolic differ-
ences, according to the anatomical localization. 27 In
addition, age is another factor that may interfere in
cell composition, since it has been observed that
younger individuals have a higher number of ADSC as
compared to older subjects. 13 In mice, researchers
noticed differences in cell composition and differenti-
ation capacity of ADSC, based on anatomical regions. 15
Therefore, it appears that human adipose tissue
is probably constituted by different subtypes of stem
cells, based on the anatomical region. Nevertheless,
more comparative studies about the nature of the
cells and the potential of differentiation of ADSC iso-
lated from adipose tissue of distinct anatomical
regions are needed. Attention should also be focused
on the type of surgical and/or laboratorial procedure
employed. 
The number of stem cells that may be obtained
from adipose tissue is clinically relevant since they
have a higher cellular proliferation rate than BMSC. 3
1. Identification, molecular characteristics and
differentiation of ADSC 
Rodbell et al. (1960) 36 introduced the initial
method for isolating cells from adipose tissue. At first,
this method was performed only with adipose tissue
samples of laboratory animals (mice, rabbits). Later,
this method was modified for use with human adipose
tissue samples (Figure 1). 
The adipose tissue is grinded and washed
extensively in phosphate-buffered saline (PBS) con-
taining penicillin/streptomycin (P/S). Next, with the
addition of collagenase, the digestion phase begins.
The tissue is incubated at 370C from 30 to 90 minutes.
After this time period, it is necessary to neutralize the
activity of collagenase by adding fetal bovine serum
(FBS). 20,21,33
Before transferring the sample to the centrifuge
tube, it is advisable to mix it to disintegrate adipose
tissue aggregates. After the material is centrifuged, it is
possible to separate adipocytes from the SVF. SVF is
formed by a heterogeneous cell population, including
circulating blood cells, fibroblasts, periocytes and
endothelial cells, as well as ADSC. 21,33
The final step for isolating ADSC is the selection
of the adherent population inside the SVF. After the
separation of SVF from the adipocytes is complete, the
sample (SVF) is incubated in ice for 10 minutes in lysis
buffer. Then, the sample is washed in PBS containing
P/S and, once again, centrifuged. Next, cellular expan-
sion is initiated in appropriate culture medium (e.g.
DMEM-LG- Dulbecos’s modified Eagle’s medium).
Cells are cultured in cell culture plaques and culture-
expanded for up to 15 passages [V].  The ADSC
obtained this way may be used in various protocols of
cell characterization (Figure 1). 33,36,37 The various sur-
face proteins considered to be ADSC markers are
shown in table 1. 9,10,17,30,31,33,34
Zhu Y et al. (2008) 32 observed that ADSC can
be maintained in culture with many growth stages,
without passage, for more than a month. During this
period, right after the second week, the authors
observed that there was an increase in protein synthe-
[III] The incidence of BMSC is estimated to be about 1 in every 100,000-500,000 nucleated cells from bone marrow 
aspirate in adults  
[IV] Surgical resection or tumescent liposuction or ultrasound assisted liposuction 
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sis and, consequently, an increase in the expression of
surface proteins. 
As a minimal prerequisite, based on flow
cytometry data analysis, MSC must express typical
antigens such as CD73, CD105, and CD90. ADSC also
express high levels of these antigens; CD13, CD29,
CD44, CD105, and CD166 are the most frequent
(Table 1). 9,10,30,31,33,34 Nonetheless, ADSC do not express
hematopoietic antigens such as CD34, CD45, and
HLA-DR, a profile also found in MSC. 
Zhu et al. (2008) 32, after 25 passages, per-
formed subculture of ADSC every 14 days, instead of
every five days, intent on obtaining a greater amount
of ADSC, keeping their phenotype and capacity of
proliferation and differentiation. 
Some authors noticed an improvement in the
growth rate and viability of ADSC with the use of
antioxidants and low concentration of calcium. 37
Several proteins may stimulate the proliferation of
ADSC, such as: 
a) Fibroblast growth factor-2 (FGF-2), by FGF-2 
receptor; 38
b) Sphingophosphorylcholine, by c-jun N 
terminal kinase activation (JNK); 39
c) Platelet-derived factor, by JNK  activation, 40 and
d) Oncostatin M, 41 by the activation of 
microtubule-associated protein kinase 
(MEK), the extracellular signal-regulated 
kinase (ERK) and by JAK3/STAT1 [VI]. 
ADSC are able to maintain their self-renewal (or
self-replication) in vitro 42 because they secrete
growth factors. The oncogenic potential of ADSC may
be reduced by the inhibition of MEk1 protein, but this
does not affect the differentiation potential of ADSC.
The longevity of human ADSC may be prolonged by
the overexpression of the catalytic subunit of the
telomerase gene. 43 Moreover, ADSC secrete other
potent growth factors, such as the vascular endothe-
lial growth factor (VEGF), hepatocyte growth factor
(HGF), and growth factor-1, which is similar to insulin
growth factor-1 (IGF-1). 44 The tumoral necrosis factor
may significantly increase the secretion of VEGF, HGF,
and IGF-1 of ADSC by the activation of p38, which is
dependent on the protein kinase mechanism. 44
There are some molecular differences between
ADSC and BMSC, although the profile of the expression
of surface proteins [VII] and genes [VIII] appears to be
similar 10,33 (Table 1). It is estimated that less than 1% of
the genes are expressed differently by ADSC and BMSC.
31 There has not been a successful specific phenotypic
characterization of ADSC in the literature, and compar-
ative studies between the expression of the gene and
surface proteins of ADSC and BMSC are rare. 10,30,31
More knowledge about the mechanisms that
regulate the biology of ADSC is necessary to perfect
and standardize laboratory techniques for the isola-
PBS (phosphate-buffered 
saline ) 
ADSC – Adipose tissue-derived stem
cells 
FIGURE 1: Flowchart of the laboratorial procedure to isolate adipose tissue-derived stem cells 
[V] Passage: in the cell culture, it is the process in which cells are dissociated, washed and cultured in new culture 
plaques, after a growth and cell proliferation cycle. The number of passages that a cultured cell lineage goes through 
indicates its age and likely stability
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17,25,46-49 have shown in vitro the ability of ADSC to dif-
ferentiate into mesenchymal cells (adipocytes,
myocytes, osteocytes, and condrocytes) and non-mes-
enchymal cells (hepatocytes, neurons, pancreatic
cells, endothelial cells, and cardiomyocytes – Table 2).
20 Rodriguez et al. (2005) showed in vivo that the
implantation of ADSC in mice restored the expression
of dystrophin in the muscle cells of the mouse. 
Before the transcription events, the process
through which stem cells can be coaxed or destined to
a specific lineage is still not fully understood. 8
However, some tissue transcription factors are known.
In stem cells, the process of proliferation, coaxing,
and terminal differentiation (lineage-specific) are reg-
ulated by a complex network of molecular interaction
that involves gene transcription modulators, tran-
scription factors, protein kinases, growth factors and
cell receptors (Figure 2). 
Runx-2, for instance, is a key transcription fac-
tor for osteogenesis involved in the differentiation of
ADSC into osteocytes, 50 whereas PPAR γ is a factor
involved in the adipogenic differentiation of ADSC.
Hong et al. (2006) 50 showed that TAZ (co-activating
transcription factor) is capable of activating the Runx-
2 transcription factor, as well as of inhibiting the tran-
scription of the PPAR γ-codifying gene.  
2. Therapeutic Perspectives
Embryonic and somatic stem cells are useful to
investigate questions in basic science and clinical
research. The use of somatic stem cells, particularly
due to practicality and the uninvolvement of ethical
and immunogenic issues, is one of the most promis-
ing areas of research about tissue regeneration and
cancer development. In this field, there is a growing
interest in the use of ADSC in studies about the devel-
opment of neoplasms, degenerative diseases, and
therapeutic applications in reconstructive surgery
(Table 2). 20
In addition, ADSC may be used in: i) basic stud-
ies that seek to understand the molecular, genetic and
epigenetic mechanisms involved in the control of the
intrinsic processes of stem cells, ii) the study of the
physiopathology of human genetic diseases, and iii)
development and tests of new drugs. Even though ther-
apeutic strategies with ADSC have not been widely test-
ed in humans, technical-scientific advances in the areas
of cellular and molecular biology, facilitated by studies
TABLE 1: Profile of the expression of protein markers
in adipose tissue-derived stem cells 
tion, characterization and manipulation of ADSC.
Such knowledge is prerequisite, not only to the cul-
ture and differentiation of a specific cell lineage, but
also to the development of a more efficient therapy. 
It is important to highlight that ADSC share
immunosuppressive properties with BMSC, 45 as well
as the deficient HLA-DR expression. Therefore, it is
likely that in the future ADSC may be made available
for allogeneic transplants due to the lower risk of
rejection. 45
The process through which ADSC differentiate
into other cells is denominated lineage-specific differ-
entiation 9 and begins with the activation of certain
transcription factors (Figure 2). Recently, researchers
* Based on the scientific literature, Barry & Murphy, 2004,9 Kern
et al., 200610; De Ugarte et al., 200330 Lee et al., 2004;31
Oedayrajsingh et al., 2006; 33 Gronthos et al., 2001,34  all the cel-
lular surface markers were verified in vitro after cell expansion.
They were not evaluated in primary cells. All the attempts to dif-
ferentiate the molecular phenotype of these cells and those similar
to fibroblasts were not successful. As a minimal prerequisite,
ADSC typically express mesenchymal markers (in bold) and
express, in a deficient way, markers of endothelial and hematopoi-
etic lineage (Source: Schäffler & Büchler, 2007 20).
Positive Expression Negative or defficient expression 
CD9 CD11b
CD10 CD14
CD13 CD19
CD29 CD31
CD44 CD34
CD49 CD45
CD54 CD79 ALFA
CD55 CD80
CD59 CD117
CD73 CD133
CD90 CD144
CD105 HLA-DR
CD106 c-kit
CD146 MyD88
CD166 STRO-1
HLA1 LIN
FIBRONECTIN HLAII 
ENDOMUCIN
ASTHMA
VIMENTIN
COLLAGEN-1
[VI] JAK3 - Janus Kinase 3- enzyme found in immune cells, responsible for the signaling process that results in the 
differentiation of leukocytes. STAT1 - Transcription factor – signal transductor and activator of the transcription that 
mediates cell responses to interferons. STAT1 interacts with the tumor suppressive protein p53 and regulates the 
expression of the genes involved in growth control and apoptosis 
[VII] Determined by FACS (fluorescence-activated cell sorting)
[VIII]Determined by micro-arrangements 
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about human somatic stem cells, may positively influ-
ence the advance of clinical research with ADSC.
CONCLUSION
Despite great advances, many important issues
about the use of ADSC in tissue bioengineering
remain unclear. These questions must be explored
before clinical tests to better direct clinical strategies.
Among the greatest current challenges, we may cite:
how to control the processes of proliferation and dif-
ferentiation of ADSC in vitro and in vivo? Which fac-
tors control these processes? Which niche factors
determine the control of its behavior? Which factors
stimulate the migration to and integration of ADSC
into the sites of tissue injury? What capacity do ADSC
have to form tumors? 
An important factor to improve ADSC research
is the standardization of surgical and laboratory meth-
ods used to isolate and characterize these cells. Along
these lines, comparative studies are extremely rele-
vant and should be conducted to evaluate surgical
procedures employed to obtain adipose tissue and to
locate the best adipose tissue donor area. Laboratory
techniques for tissue preparation to isolate and iden-
tify ADSC, cell culture techniques in scale and purity
degrees for clinical application, and the methods that
evaluate the quality of the cells to be implanted  (e.g.
evaluation of cell differentiation potential, presence of
genetic or epigenetic alterations, etc) should also be
standardized. 
The comprehension of the molecular mecha-
nisms that regulate the self-renewal and differentia-
tion of ADSC, as well as their interaction with the cell
niche, is equally relevant. This basic knowledge may
help the development of new therapies and the evalu-
ation of biosecurity issues in future clinical protocols.
Fonte: Schäffler & Büchler, 200720
Notas:
ADD1 - adipocyte determination- and differentiation-
dependent factor-1 
SREBP1c - sterol regulatory element-binding protein-1
BMP- bone morphogenetic protein
C/EBP, CCAAT - enhancer-binding protein 
Dlx5 - distal-less homeobox-5 
ERK - extracellular signal-regulated kinase
FGF-2 - fibroblast growth factor-2
FGF-2-R - fibroblast growth factor-2 receptor 
JNK - c-jun N-terminal kinase 
KLF - Kruppel-like transcription factor
KROX-20 - Krox-20- homolog Drosophila 
MEF2, MADS box transcription enhancer factor-2; 
MEK - microtubule-associated protein/extracellular signal-
regulated kinase
MRF4 - muscle regulatory factor-4
Myf5 - myogenic factor-5
MyoD - myogenic differentiation antigen
PPAR-_ - peroxisome proliferator-activated receptor 
RXR_- retinoid X receptor
Shh- sonic hedgehog 
STAT-1 - signal transducer and activator of transcription-1
TAZ - transcriptional coactivator with PDZ-binding motif 
TGF - transforming growth factor
FIGURE 2: Molecular regulation of the proliferation, lineage-specific coaxing, and differentiation of adipose tissue-derived stem cells
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Differentiation factors type of differentiation clinical potential
Insulin, IBMX (3-isobutil-1-methylxanthine), Adipogenic Reconstructive surgeries, skin filling
dexamethasone, rosiglitazone, indomethasone
bone morphogenetic protein, fibroblast Chondrogenic Reconstructive surgeries, joint repair in 
growth factor, transforming growth degenerative diseases
factor, dexamethasone, insulin growth factor
1,25 dihydroxycholecalciferol b β,  Osteogenic Bone tissue regeneration in degenerative  
glycerophosphate, ascorbic acid, bone diseases, tumors and traumas
morphogenetic protein 2, valproic acid
? Myogenic Regeneration in degenerative diseases such as 
Duchenne muscular dystrophy 
stem cell factor, interleukin-3, Cardiomyogenic Regeneration of cardiac muscle after acute  
interleukin-6 myocardial infarction 
? Vascular/endothelial Neovascularization/ ischemic diseases  
valproic acid, insulin, hydrocortisone, 
epidermal growth factor, FGF Neurogenic Chronic-degenerative diseases and central and   
peripheral nervous system traumas
Activin-A, exedin-4, pentagastrin, Pancreatic/endocrine Diabetes mellitus type 1
hepatocyte growth factor, 
nicotinamide, glucose
hepatocyte growth factor , oncostatin, Hepatic Hepatic regeneration
dimethyl sulphoxide
? Hematopoietic Hematopoetic reconstitution
TABLE 2: Experimental factors to induce the differentiation of adipose tissue-derived stem cells 
Source: Schäffler & Büchler, 2007 20
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